Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib

Proteotoxic stress (PS) is generated in cells under a variety of conditions involving accumulation of misfolded proteins. To avoid the toxicity of unmitigated PS, cells activate the heat shock response (HSR). HSR involves upregulation of factors such as ubiquitin and the non-housekeeping chaperone Hsp70 which assist with metabolism of aberrant proteins. The PS-HSR axis is a potential anticancer treatment target since many tumor cells display constitutive PS and dependence on HSR due to their rapid rates of proliferation and translation. In fact, induction of PS via stimulation of protein misfolding (hyperthermia), inhibition of proteasomes (bortezomib) or inhibition of Hsp90 (geldanamycin) have all been considered or used for cancer treatment. We found that combination of bortezomib with an inducer of protein misfolding (hyperthermia or puromycin) resulted in enhanced PS. HSR was also induced, but could not mitigate the elevated PS and the cells died via largely p53-independent apoptosis. Thus, combination treatments were more cytotoxic in vitro than the component single treatments. Consistent with this, combination of non-toxic doses of puromycin with bortezomib significantly increased the antitumor activity of bortezomib in a mouse model of multiple myeloma. These results provide support for using combination treatments that disrupt the balance of PS and HSR to increase the therapeutic index of anticancer therapies.

[1]  J. Monbaliu,et al.  Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib , 2007, Cancer Chemotherapy and Pharmacology.

[2]  J. Sarkaria,et al.  Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways , 2006, Molecular Cancer Therapeutics.

[3]  R. Morimoto,et al.  Transcriptional regulation of heat shock genes. A paradigm for inducible genomic responses. , 1992, The Journal of biological chemistry.

[4]  Bin Jiang,et al.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.

[5]  K. Bhalla,et al.  Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection , 2006, Cell Death and Differentiation.

[6]  C. Marshall.  Tumor suppressor genes , 1991, Cell.

[7]  Yili Yang,et al.  Targeting the ubiquitin‐proteasome system for cancer therapy , 2009, Cancer science.

[8]  N. Munshi,et al.  Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib , 2009, Clinical Cancer Research.

[9]  R. Fonseca,et al.  Primary therapy with single agent bortezomib as induction, maintenance, and re-Induction in patients with high risk myeloma: results of the ECOG E2A02 trial , 2010, Leukemia.

[10]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Wek,et al.  Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. , 2005, The Journal of biological chemistry.

[12]  D. Esseltine,et al.  Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Morimoto,et al.  The human heat shock protein hsp70 interacts with HSF, the transcription factor that regulates heat shock gene expression. , 1992, Genes & development.

[14]  Hongmao Sun,et al.  Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Jakubowiak,et al.  Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies , 2010, Leukemia & lymphoma.

[16]  G. Opelz,et al.  Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells , 2008, Journal of cellular biochemistry.

[17]  K. McEntee,et al.  Multiple independent regulatory pathways control UBI4 expression after heat shock in Saccharomyces cerevisiae , 1999, Molecular microbiology.

[18]  D. Reece,et al.  Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. , 2009, Blood.

[19]  A. Gudkov,et al.  Different Effect of Proteasome Inhibition on Vesicular Stomatitis Virus and Poliovirus Replication , 2008, PloS one.

[20]  D. Neuberg,et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. , 2002, Cancer research.

[21]  Keiji Tanaka,et al.  Proteasomes and Molecular Chaperones : Cellular Machinery Responsible for Folding and Destruction of Unfolded Proteins , 2003, Cell cycle.

[22]  K. Anderson,et al.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.

[23]  L. Hightower.  Cultured animal cells exposed to amino acid analogues or puromycin rapidly synthesize several polypeptides , 1980, Journal of cellular physiology.

[24]  R. Wittig,et al.  The Role of Glucose Metabolism and Glucose-Associated Signalling in Cancer , 2008, Perspectives in medicinal chemistry.

[25]  D. Moskophidis,et al.  Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors , 2007, Oncogene.

[26]  M. Horowitz,et al.  Heat shock proteins and the heat shock response during hyperthermia and its modulation by altered physiological conditions. , 2007, Progress in brain research.

[27]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[28]  H. Lenz.  Clinical update: proteasome inhibitors in solid tumors. , 2003, Cancer treatment reviews.

[29]  P. Workman,et al.  Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. , 2008, Cancer cell.

[30]  E. Craig,et al.  The heat shock response. , 1985, CRC critical reviews in biochemistry.

[31]  P. Richardson,et al.  Proteasome Inhibition in the Treatment of Cancer , 2005, Cell cycle.

[32]  J. Monbaliu,et al.  Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib. , 2007, Cancer chemotherapy and pharmacology.

[33]  R. Place,et al.  Hsp70B′ regulation and function , 2007, Cell stress & chaperones.

[34]  J. Hess,et al.  Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. , 2004, Blood.

[35]  S-G Hwang,et al.  Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition , 2000, Leukemia.

[36]  C. Erlichman,et al.  Cisplatin abrogates the geldanamycin-induced heat shock response , 2008, Molecular Cancer Therapeutics.

[37]  S. Lindquist,et al.  Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of Carcinogenesis , 2007, Cell.

[38]  U. Lopes,et al.  p53-dependent Induction of Apoptosis by Proteasome Inhibitors* , 1997, The Journal of Biological Chemistry.

[39]  S. Calderwood,et al.  Expression of a Dominant Negative Heat Shock Factor-1 Construct Inhibits Aneuploidy in Prostate Carcinoma Cells* , 2004, Journal of Biological Chemistry.

[40]  R. Wek,et al.  Phosphorylation of the α-Subunit of the Eukaryotic Initiation Factor-2 (eIF2α) Reduces Protein Synthesis and Enhances Apoptosis in Response to Proteasome Inhibition* , 2005, Journal of Biological Chemistry.

[41]  R. Meller,et al.  Ubiquitin-proteasome system as a modulator of cell fate. , 2008, Current opinion in pharmacology.

[42]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[43]  S. C. Lakhotia,et al.  Heat shock genes — integrating cell survival and death , 2007, Journal of Biosciences.

[44]  T. Pugh,et al.  Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. , 2010, International journal of radiation oncology, biology, physics.

[45]  A. Gudkov,et al.  Anti-malaria drug blocks proteotoxic stress response: Anti-cancer implications , 2009, Cell cycle.

[46]  R. Morimoto,et al.  Role of the heat shock response and molecular chaperones in oncogenesis and cell death. , 2000, Journal of the National Cancer Institute.

[47]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[48]  A. Goldberg,et al.  Protein degradation and protection against misfolded or damaged proteins , 2003, Nature.

[49]  K. Black,et al.  Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM) , 2005, Oncogene.

[50]  Richard D. Vaughan-Jones,et al.  Regulation of tumor pH and the role of carbonic anhydrase 9 , 2007, Cancer and Metastasis Reviews.

[51]  R. Morimoto,et al.  Stress-induced activation of the heat-shock response: cell and molecular biology of heat-shock factors. , 1999, Biochemical Society symposium.

[52]  C. Harris,et al.  Oncogenes and tumor-suppressor genes. , 1991, Environmental health perspectives.

[53]  T. Fojo,et al.  Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. , 1998, Experimental cell research.

[54]  M. Carroll,et al.  p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. , 2007, Blood.

[55]  Jian Yu,et al.  Differential Apoptotic Response to the Proteasome Inhibitor Bortezomib (VELCADETM, PS-341) in Bax-Deficient and p21-Deficient Colon Cancer Cells , 2003, Cancer biology & therapy.